Impact of co-morbidity on mortality after XXXX surgery.

@entity1 @entity10189 @entity712 @entity455 @entity5 @entity957 @entity409 @entity358 @entity583 @entity420
BACKGROUND: There is limited knowledge of how co-morbidities influence survival after surgery for @entity5 . This population-based cohort study investigated how Charlson co-morbidity index and specific co-morbidities influenced all-cause and disease-specific mortality. METHODS: Data from all @entity1 who underwent @entity5 surgery in Sweden in 1987-2010, with follow-up until 2012, came from histopathology records, operation charts and nationwide registers. Associations between co-morbidities (Charlson co-morbidity index) and mortality were analysed using Cox proportional hazard regression with adjustment for potential confounding, and presented as hazard ratio (HR) with 95 per cent c.i. RESULTS: Among 1822 @entity1 there were 1474 deaths (80  9 per cent), of which 1139 (77  3 per cent) occurred between 91 days and 5 years after surgery. Overall all-cause mortality was increased in @entity1 with a Charlson score of 2 or more (HR 1  24, 95 per cent c.i. 1  08 to 1  42), and those with a history of @entity583 (HR 1  23, 1  01 to 1  49) or @entity712 (HR 1  31, 1  04 to 1  67). @entity1 with @entity957 had increased overall all-cause mortality if they had been diagnosed with @entity5 (HR 1  36, 1  09 to 1  71), whereas those with @entity420 did not. A Charlson score of 1 or exposure to the co-morbidity groups peripheral @entity455 , @entity358 , connective tissue disease, @entity10189 , @entity409 did not increase mortality. The disease-specific results were generally similar to the all-cause mortality data. CONCLUSION: Co-morbidity with a Charlson score of 2 or more, previous @entity583 and @entity712 were associated with increased mortality after @entity5 surgery undertaken with curative intent.
